Literature DB >> 10610719

Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease.

G M Yousef1, L Y Luo, S W Scherer, G Sotiropoulou, E P Diamandis.   

Abstract

The cDNA for the zyme/protease M/neurosin gene (HGMW-approved symbol PRSS9) has recently been identified. Zyme appears to play a role in Alzheimer disease as well as in breast cancer. In this paper, we describe the complete genomic organization of the zyme gene. Zyme spans 10.5 kb of genomic sequence on chromosome 19q13.3-q13.4. The gene consists of seven exons, the first two of which are untranslated. All splice junctions follow the GT/AG rule, and the intron phases are identical to those of many other genes belonging to the same family, i.e., the kallikreins, NES1, and neuropsin. Fine-mapping of the genomic locus indicates that zyme lies upstream of the NES1 gene and downstream from the PSA and KLK2 genes. Tissue expression studies indicate that zyme is expressed mainly in brain tissue, including spinal cord and cerebellum, in mammary gland, and in kidney and uterus. Zyme is regulated by steroid hormones in the breast carcinoma cell line BT-474. Estrogens and progestins, and to a lesser extent androgens, up-regulate the zyme gene in a dose-dependent manner. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10610719     DOI: 10.1006/geno.1999.6012

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  12 in total

1.  Substrate specificity of human kallikreins 1 and 6 determined by phage display.

Authors:  Hai-Xin Li; Bum-Yeol Hwang; Gurunathan Laxmikanthan; Sachiko I Blaber; Michael Blaber; Pavel A Golubkov; Pengyu Ren; Brent L Iverson; George Georgiou
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

2.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

3.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

4.  Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.

Authors:  David Pépin; Zhong-Qi Shao; Geneviève Huppé; Andrea Wakefield; Chee-Wui Chu; Zahra Sharif; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

5.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

6.  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.

Authors:  Carola H Schrader; Markus Kolb; Karim Zaoui; Christa Flechtenmacher; Niels Grabe; Klaus-Josef Weber; Thomas Hielscher; Peter K Plinkert; Jochen Hess
Journal:  Mol Cancer       Date:  2015-05-20       Impact factor: 27.401

7.  Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.

Authors:  Ai Zhao; Fahai Chen; Chunhong Ning; Haiming Wu; Huanfang Song; Yanqing Wu; Rong Chen; Kaihua Zhou; Xiaoling Xu; Yinxiang Lu; Jimin Gao
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

8.  Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.

Authors:  B R Hoffman; D Katsaros; A Scorilas; P Diamandis; S Fracchioli; I A Rigault de la Longrais; T Colgan; M Puopolo; G Giardina; M Massobrio; E P Diamandis
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

9.  Plasmatic level of neurosin predicts outcome of mild cognitive impairment.

Authors:  Manuel Menendez-Gonzalez; Patricia Castro-Santos; Maria Teresa Calatayud; Pablo Perez-Piñera; Renee Ribacoba; Marta Martinez-Rivera; Carmen Gutierrez; Alfonso Lopez-Muñiz; Ana Suarez
Journal:  Int Arch Med       Date:  2008-07-11

10.  Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance.

Authors:  L-Y Luo; E P Diamandis; M P Look; A P Soosaipillai; J A Foekens
Journal:  Br J Cancer       Date:  2002-06-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.